NZ331546A - 4-phenylamino pyridopyrimidine derivatives, medicaments containing these compounds, their use and process for their production - Google Patents
4-phenylamino pyridopyrimidine derivatives, medicaments containing these compounds, their use and process for their productionInfo
- Publication number
- NZ331546A NZ331546A NZ331546A NZ33154697A NZ331546A NZ 331546 A NZ331546 A NZ 331546A NZ 331546 A NZ331546 A NZ 331546A NZ 33154697 A NZ33154697 A NZ 33154697A NZ 331546 A NZ331546 A NZ 331546A
- Authority
- NZ
- New Zealand
- Prior art keywords
- crc
- phenylamino
- production
- compounds
- pyridopyrimidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to 4-phenylamino pyridopyrimidine derivatives of the formula shown, where Ra is H or CH3, Rb is optionally substituted phenyl or phenylalkyl, A and B together are a bridge selected from -N=CRc-CH=CH-, -CH=N-CRc=CH-, -CH=CRc-N=CH-, -CH-=CH-CRc=N- or -CH=N-CRc=N-, and their tautomers, stereoisomers and salts, especially their physiologically acceptable salts with inorganic or organic acids or bases, having valuable pharmacological properties, especially an inhibitory effect on signal transduction produced by tyrosine kinases, their use in the treatment of disorders, especially tumours, and their production.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1996108631 DE19608631A1 (en) | 1996-03-06 | 1996-03-06 | New (heterocyclyl- pyrimidino or -pyrido)fused pyrimidine derivatives |
DE19629652A DE19629652A1 (en) | 1996-03-06 | 1996-07-23 | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation |
PCT/EP1997/001057 WO1997032881A1 (en) | 1996-03-06 | 1997-03-03 | 4-amino pyrimidine derivates, medicaments containing these compounds, their use and process for their production |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ331546A true NZ331546A (en) | 2000-03-27 |
Family
ID=26023531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ331546A NZ331546A (en) | 1996-03-06 | 1997-03-03 | 4-phenylamino pyridopyrimidine derivatives, medicaments containing these compounds, their use and process for their production |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0885226A1 (en) |
JP (1) | JP2000506847A (en) |
KR (1) | KR19990087550A (en) |
CN (1) | CN1212695A (en) |
AU (1) | AU710274B2 (en) |
BG (1) | BG102708A (en) |
BR (1) | BR9708312A (en) |
CA (1) | CA2243994A1 (en) |
CZ (1) | CZ281798A3 (en) |
DE (1) | DE19629652A1 (en) |
EE (1) | EE9800277A (en) |
HU (1) | HUP9901820A3 (en) |
IL (1) | IL125404A0 (en) |
NO (1) | NO984084D0 (en) |
NZ (1) | NZ331546A (en) |
PL (1) | PL328771A1 (en) |
SK (1) | SK120598A3 (en) |
TR (1) | TR199801749T2 (en) |
WO (1) | WO1997032881A1 (en) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT880508E (en) | 1996-02-13 | 2003-07-31 | Astrazeneca Ab | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS |
AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
EP1396489A1 (en) * | 1999-01-27 | 2004-03-10 | Pfizer Products Inc. | Heteroaromatic bicyclic derivatives useful as anticancer agents |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
WO2001032651A1 (en) | 1999-11-05 | 2001-05-10 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
KR20060030482A (en) * | 2003-06-24 | 2006-04-10 | 뉴로서치 에이/에스 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
US7763616B2 (en) * | 2005-02-16 | 2010-07-27 | Schering Corporation | Piperazine-piperidines with CXCR3 antagonist activity |
MX2011004824A (en) | 2008-11-07 | 2012-01-12 | Triact Therapeutics Inc | Use of catecholic butane derivatives in cancer therapy. |
JP5697601B2 (en) * | 2008-12-01 | 2015-04-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 2,5-Diamino-substituted pyrido [4,3-D] pyrimidines as autotaxin inhibitors against cancer |
EP2400985A2 (en) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
JP2012519170A (en) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | INSITU method for monitoring EMT status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519281A (en) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Methods for identifying mesenchymal tumor cells or agents that inhibit their production |
US20120064072A1 (en) | 2009-03-18 | 2012-03-15 | Maryland Franklin | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor |
JP2013510564A (en) | 2009-11-13 | 2013-03-28 | パンガエア ビオテック、ソシエダッド、リミターダ | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
CA2845179A1 (en) | 2011-08-31 | 2013-03-07 | Genentech, Inc. | Diagnostic markers |
SG11201400996SA (en) | 2011-09-30 | 2014-04-28 | Genentech Inc | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | Cancer therapy |
WO2014147246A1 (en) | 2013-03-21 | 2014-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
EP3237638B1 (en) | 2014-12-24 | 2020-01-15 | F.Hoffmann-La Roche Ag | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
SG10201913491PA (en) | 2016-12-22 | 2020-03-30 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
WO2019051291A1 (en) | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
EP3788053B1 (en) | 2018-05-04 | 2024-07-10 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
MA52501A (en) | 2018-05-04 | 2021-03-10 | Amgen Inc | KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE |
CA3099045A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
ES2938987T3 (en) | 2018-06-01 | 2023-04-18 | Amgen Inc | KRAS G12c inhibitors and methods of use thereof |
MA52780A (en) | 2018-06-11 | 2021-04-14 | Amgen Inc | KRAS G12C INHIBITORS FOR CANCER TREATMENT |
CA3100390A1 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer |
JP2022512584A (en) | 2018-10-04 | 2022-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | EGFR inhibitor for treating keratoderma |
JP7516029B2 (en) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds |
JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
WO2020106640A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US20220002311A1 (en) | 2018-12-20 | 2022-01-06 | Amgen Inc. | Kif18a inhibitors |
JP2022514268A (en) | 2018-12-20 | 2022-02-10 | アムジエン・インコーポレーテツド | KIF18A inhibitor |
EA202191730A1 (en) | 2018-12-20 | 2021-08-24 | Эмджен Инк. | KIF18A INHIBITORS |
MA54546A (en) | 2018-12-20 | 2022-03-30 | Amgen Inc | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS |
CN113767100A (en) | 2019-03-01 | 2021-12-07 | 锐新医药公司 | Bicyclic heteroaryl compounds and uses thereof |
US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
CA3225293A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
US20220289724A1 (en) | 2019-08-02 | 2022-09-15 | Amgen Inc. | Kif18a inhibitors |
WO2021026099A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
US20220281843A1 (en) | 2019-08-02 | 2022-09-08 | Amgen Inc. | Kif18a inhibitors |
MX2022001302A (en) | 2019-08-02 | 2022-03-02 | Amgen Inc | Pyridine derivatives as kif18a inhibitors. |
JP2022552873A (en) | 2019-10-24 | 2022-12-20 | アムジエン・インコーポレーテツド | Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer |
WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
CR20220241A (en) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Ras inhibitors |
TW202132315A (en) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras inhibitors |
KR20220100903A (en) | 2019-11-08 | 2022-07-18 | 레볼루션 메디슨즈, 인크. | Bicyclic heteroaryl compounds and uses thereof |
MX2022005726A (en) | 2019-11-14 | 2022-06-09 | Amgen Inc | Improved synthesis of kras g12c inhibitor compound. |
CA3158188A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
BR112022010086A2 (en) | 2020-01-07 | 2022-09-06 | Revolution Medicines Inc | SHP2 INHIBITOR DOSAGE AND CANCER TREATMENT METHODS |
WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
PE20231207A1 (en) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | INDOLIC DERIVATIVES AS RAS INHIBITORS IN CANCER TREATMENT |
AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
JP2024516450A (en) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | Covalent RAS inhibitors and uses thereof |
AR125787A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
CR20230570A (en) | 2021-05-05 | 2024-01-22 | Revolution Medicines Inc | Ras inhibitors |
AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
DE4431867A1 (en) * | 1994-09-07 | 1996-03-14 | Thomae Gmbh Dr K | New 4-amino-pyrimido-pyrimidine derivs. |
-
1996
- 1996-07-23 DE DE19629652A patent/DE19629652A1/en not_active Ceased
-
1997
- 1997-03-03 AU AU19251/97A patent/AU710274B2/en not_active Ceased
- 1997-03-03 BR BR9708312A patent/BR9708312A/en not_active IP Right Cessation
- 1997-03-03 TR TR1998/01749T patent/TR199801749T2/en unknown
- 1997-03-03 EP EP97907066A patent/EP0885226A1/en not_active Ceased
- 1997-03-03 CA CA002243994A patent/CA2243994A1/en not_active Abandoned
- 1997-03-03 IL IL12540497A patent/IL125404A0/en unknown
- 1997-03-03 KR KR1019980706987A patent/KR19990087550A/en not_active Application Discontinuation
- 1997-03-03 EE EE9800277A patent/EE9800277A/en unknown
- 1997-03-03 SK SK1205-98A patent/SK120598A3/en unknown
- 1997-03-03 CN CN97192787A patent/CN1212695A/en active Pending
- 1997-03-03 HU HU9901820A patent/HUP9901820A3/en unknown
- 1997-03-03 JP JP9531444A patent/JP2000506847A/en active Pending
- 1997-03-03 NZ NZ331546A patent/NZ331546A/en unknown
- 1997-03-03 CZ CZ982817A patent/CZ281798A3/en unknown
- 1997-03-03 WO PCT/EP1997/001057 patent/WO1997032881A1/en not_active Application Discontinuation
- 1997-03-03 PL PL97328771A patent/PL328771A1/en unknown
-
1998
- 1998-08-20 BG BG102708A patent/BG102708A/en unknown
- 1998-09-04 NO NO984084A patent/NO984084D0/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUP9901820A3 (en) | 2001-10-29 |
EE9800277A (en) | 1999-02-15 |
AU1925197A (en) | 1997-09-22 |
WO1997032881A1 (en) | 1997-09-12 |
CZ281798A3 (en) | 1999-02-17 |
BR9708312A (en) | 1999-08-03 |
CA2243994A1 (en) | 1997-09-12 |
KR19990087550A (en) | 1999-12-27 |
BG102708A (en) | 1999-09-30 |
NO984084L (en) | 1998-09-04 |
DE19629652A1 (en) | 1998-01-29 |
EP0885226A1 (en) | 1998-12-23 |
TR199801749T2 (en) | 1998-12-21 |
SK120598A3 (en) | 1999-06-11 |
HUP9901820A2 (en) | 1999-09-28 |
NO984084D0 (en) | 1998-09-04 |
PL328771A1 (en) | 1999-02-15 |
CN1212695A (en) | 1999-03-31 |
AU710274B2 (en) | 1999-09-16 |
JP2000506847A (en) | 2000-06-06 |
IL125404A0 (en) | 1999-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ331546A (en) | 4-phenylamino pyridopyrimidine derivatives, medicaments containing these compounds, their use and process for their production | |
MX9807073A (en) | Pyrimido[5,4-d]pyrimidines, medicaments containing these compounds, their use and process for their production | |
MEP58708A (en) | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof | |
MY123642A (en) | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, and processes for preparing them. | |
EA200300671A1 (en) | HINAZOLIN DERIVATIVES CONTAINING THESE COMPOUNDS MEDICINES, THEIR USE AND METHOD OF THEIR PREPARATION | |
MEP45508A (en) | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof | |
NO984081L (en) | Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and method of preparation thereof | |
BG105765A (en) | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | |
CA2417652A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
WO1993000330A3 (en) | Azanorbornane derivatives | |
EE9700211A (en) | Pyrimido [5,4-d] pyrimidines, drugs containing these compounds, their use and method for their preparation | |
FI941022A0 (en) | Spirocyclic piperidine derivatives | |
NO991732L (en) | New heterocyclylmethyl substituted pyrazole derivatives | |
DE69617731D1 (en) | NEW HETEROCYCLIC DERIVATIVES AND THEIR MEDICAL APPLICATION | |
AU2001295482A1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof | |
CA2417050A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
RU94042907A (en) | Imidazopyridine derivatives, method of their synthesis, pharmaceutical composition and method of its preparing | |
RU94019981A (en) | Imidazopyridine derivatives, method of their synthesis, pharmaceutical composition and a method of its preparing | |
NO164027C (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC TRICYCLIC PYRIDAZOPYRIDONE DERIVATIVES. | |
HUP0300392A2 (en) | Benzo[a]phenazin-11-carboxamide derivatives, their use for producing pharmaceutical compositions with effect joint inhibitors of topomerase i and ii, process for their preparation and their intermediates | |
NO20055514L (en) | Piperazine derivatives and their use in the treatment of neurological and psychiatric disorders | |
MY140484A (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
EA200100830A1 (en) | DERIVATIVES OF 4-AMINOHINAZOLINE AND QUINOLINE, PROVIDING AN INHIBITING ACTION TO ALARM CONVERSION, MEDIED BY TYROSINKINASE |